molecules of the month


bifunctional, Gag-Pol allosteric glue

NNRTI + nanomolar ex vivo HIV-1 TACK activity

HTS of >6K NNRTIs for TACK activity

Sci. Transl. Med., February 22, 2023

Merck & Co. Inc., Rahway, NJ

PYR02, bifunctional, Gag-Pol allosteric glue, NNRTI + nanomolar ex vivo HIV-1 TACK activity, MERCK & CO. INC., RAHWAY, NJ
5 mins read

Harnessing a novel mechanism for HIV eradication with a new class of bifunctional molecules. Modern antiretroviral therapies (ARTs) efficiently block HIV-1 replication, but are not completely curative because they can’t deplete viral reservoirs hidden from the immune system within the host genome. PYR01 is an HIV antiviral which, unlike traditional HIV drugs, is able to selectively kill HIV-1-infected cells that serve as cure-preventing viral reservoirs, in addition to the early-stage antiviral activity. This non-nucleoside reverse transcriptase inhibitor (NNRTI) is able to accomplish this through optimized potency for a secondary allosteric glue function that promotes dimerization of reverse transcriptase (RT), premature intracellular HIV-1 protease activation, cleavage and activation of host proteins including the CARD8 inflammasome, ultimately leading to pyroptotic cell death.…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: